Search Results

Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, announced that it has received encouraging feedback from the U.S. FDA following a recent Type C meeting with the Agency to directly proceed into a pivotal phase III registration study with its radiopharmaceutical diagnostic Ga68-PentixaFor in Primary Aldosteronism.

Eckert & Ziegler and Nucleus RadioPharma signed extensive supply agreements for major therapeutic radioisotopes.

Eckert & Ziegler and PharmaLogic Holdings Corp. have signed a reservation agreement for the supply of the therapeutic radioisotope Actinium-225.

Eckert & Ziegler and a subsidiary of POINT Biopharma Global Inc. have signed an agreement on the supply of Actinium-225.

RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, has expanded its radiopharmaceutical contract development and manufacturing

Armed with the latest biological knowledge and cutting-edge computational techniques—and, of course, investor dollars—these six biotechs are playing in the largely underappreciated longevity space, developing therapies that may improve the quality of aging.

NorthStar Medical Radioisotopes, LLC and Eckert & Ziegler Isotope Technologies Dresden announced an agreement for the purchase of hot cells and related equipment for NorthStar’s dedicated non-carrier-added actinium-225 production facility.

Telix Pharmaceuticals Limited announces a global clinical supply agreement with Berlin-based Eckert & Ziegler Strahlen- und Medizintechnik AG for highly pure no-carrier-added lutetium-177, a therapeutic isotope used in Telix’s portfolio of molecularly targeted radiation investigational products.